Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced positive clinical data for its CLTX CAR-T in heavily pretreated, late-stage, recurrent glioblastoma patients. …
Chimeric announces positive preliminary data for CLTX CAR-T in brain cancer trial
October 23, 2023 Australian Biotech
Latest Video
New Stories
-
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News